An observational study in Obesity, Morbid, sponsored by Laval University. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Laval University · Observational
Among 32 studies in Obesity, Morbid with a site in Canada — 7 open to participants now, 10 under way, none of them phase 3. Obesity, Morbid · Canada.
Among the 32 studies in Obesity, Morbid with a site in Canada, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2026, is one of 10 observational ones, and was the 32nd registered.
941 studies on the registry are indexed under Obesity, Morbid; 163 are open to participants now.
Browse Obesity, Morbid studies →7 of the 32 studies in Obesity, Morbid with a site in Canada are open now. Recruiting first, the newest first:
Laval University · Sites in Canada
Laval University · Sites in Canada
CHU de Quebec-Universite Laval · Sites in Canada
Nova Scotia Health Authority · Sites in Canada
CHU de Quebec-Universite Laval · Sites in Canada
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 150 is above the median of 80 across 311 observational studies indexed under Obesity, Morbid.
Median enrollment 57 across the 22 interventional studies, 145 across the 10 observational. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 32 have an industry lead sponsor. The 10 most frequent:
Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.
Laval University has 9 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
3 of the studies in Obesity, Morbid with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05242835Laval UniversityManagement of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery | 2027-01 |
| NCT05120492Nova Scotia Health AuthorityOptimal Management of Extreme Obesity and Severe Knee Osteoarthritis Feasibility Trial | 2027-07 |
| NCT06002906University Health Network, TorontoThe Use of Indocyanine Green to Visualize Blood Flow to the Gastrojejunostomy During Bariatric Surgery. | 2027-07-03 |
Among the 32 studies in Obesity, Morbid with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Despite global efforts, the prevalence of obesity continues to rise, with rates in Canada tripling over the past three decades. In addition to the well-established risk of cardiometabolic conditions such as heart disease and diabetes, obesity has been associated with cognitive decline and an increased risk of dementia later in life. Sleeve gastrectomy, the most widely used surgical treatment for severe obesity, has proven effective in promoting significant weight loss and improving overall health. Emerging research, including our recent brain imaging study, suggests that this surgery may also have a positive impact on brain health. Our findings demonstrated significant improvements, with patients experiencing reductions in brain age by 2.9 and 5.6 years 12 and 24 months post-surgery, respectively. Despite these promising results, the long-term effects of sleeve gastrectomy on brain health and cognitive function remains poorly understood. While some patients experience cognitive improvements following surgery, others do not, and the factors driving this variability remain unknown.
This proposal aims to comprehensively investigate the impact of bariatric surgery on brain health by examining its cognitive consequences, determinants, and drivers. Understanding the key factors that contribute to brain health improvements after bariatric surgery is essential for optimizing its benefits, preventing relapse and developing personalized interventions to maintain or enhance brain health in individuals living with obesity.
Participants with severe obesity scheduled to undergo SG at the Institut universitaire de cardiologie et pneumologie de Québec - Université Laval (IUCPQ-ULaval).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vertical sleeve gastrectomy
Change in Estimated Brain Age
Difference between MRI-predicted brain age and chronological age based (delta age, years) derived from a validated machine learning model based on MRI modalities.
Time frame: Baseline to 36 months
Change in Executive Function Composite Score
Composite z-score derived from the Stroop Color-Word Interference test, Trail Making Test Part B and Digit Span Test ( z-score change).
Time frame: Baseline to 36 months
Change in Processing Speed Composite Score
Composite z-score derived from the Digit Symbol Substitution Test, Trail Making Test Part A, Stroop Color-Word Interference (z-score change).
Time frame: Baseline to 36 months
Change in Memory Composite Score
Composite z-score derived from the Rey Auditory Verbal Learning Test (z-score change).
Time frame: Baseline to 36 months
Change in Global Cognition
Montreal Cognitive Assessment (MoCA) score (0-30), with higher scores indicating better cognitive performance.
Time frame: Baseline to 36 months
Change in White Matter Fractional Anisotropy (FA)
Mean fractional anisotropy (FA) derived from diffusion tensor imaging (dimensionless, 0-1); Higher FA values generally reflect greater white matter microstructural organization and fiber tract integrity.
Time frame: Baseline to 36 months
Change in White Matter Mean Diffusivity (MD)
Mean diffusivity (MD; mm²/s) derived from diffusion tensor imaging. Higher MD values generally reflect reduced white matter microstructural integrity and increased water diffusion within tissue.
Time frame: Baseline to 36 months
Change in Grey Matter Density
Grey matter density measured using voxel-based morphometry derived from T1-weighted structural MRI (arbitrary units).
Time frame: Baseline to 36 months
Change in Grey Matter Cortical Thickness and Surface Area
Mean cortical thickness (mm) and total surface area (mm²) derived from T1-weighted MRI.
Time frame: Baseline to 36 months
Change in White Matter Hyperintensity Volume
Total white matter hyperintensity volume (mm3) segmented from 3D FLAIR MRI.
Time frame: Baseline to 36 months
Change in Cerebral Artery Diameter
Mean arterial lumen diameter (mm) measured in predefined cerebral arteries using TOF-MRA.
Time frame: Baseline to 36 months
Change in Cerebral Artery Volume
Total cerebral arterial volume (mm³) measured from TOF-MRA using automated vessel segmentation.
Time frame: Baseline to 36 months
Change in Cerebral Blood Flow
Regional and whole-brain cerebral blood flow (mL/100g/min) derived from ASL sequences.
Time frame: Baseline to 36 months
Change in Brain Iron Content as Measured by QMRI Multi-Parameter Mapping Protocol
Magnetic susceptibility derived from quantitative susceptibility mapping (QSM), a surrogate marker of cerebral iron content (seconds).
Time frame: Baseline to 36 months
Change in Brain Water Content as Measured by QMRI Multi-Parameter Mapping Protocol
Quantitative MRI estimate of brain Water content (%).
Time frame: Baseline to 36 months
Change in Brain Myelin Integrity as Measured by QMRI Multi-Parameter Mapping Protocol
Myelin quantitative MRI measure (myelin water fraction, %).
Time frame: Baseline to 36 months
Change in Body Mass Index
BMI (kg/m2)
Time frame: Baseline to 36 months
Change in Percent Excess Weight Loss
Excess weight loss (%)
Time frame: Baseline to 36 months
Change in Body Composition
Total weight (kg), Fat mass (kg) measured by bioimpedance or DXA.
Time frame: Baseline to 36 months
Change in Adiposity
Waist, Hip and Neck circumference (cm).
Time frame: Baseline to 36 months
Change in Glycemic Profile (blood samples)
Fasting glucose (mmol/L)
Time frame: Baseline to 36 months
Change in HbA1c
HbA1c (%)
Time frame: Baseline to 36 months
Change in Insulin (Blood samples)
Fasting Insulin (pmol/L)
Time frame: Baseline to 36 months
Change in HOMA-IR index
HOMA-IR index (fasting glucose (mmol/L) x fasting insulin (pmol/L) / 135)
Time frame: Baseline to 36 months
Change in Lipid Profile (blood samples)
Fasting Total Cholesterol (mmol/L), High Density Lipoprotein (HDL) cholesterol (mmol/L), Low Density Lipoprotein (LDL) cholesterol (mmol/L), Triglycerides (mmol/L), Apolipoprotein-B (g/L).
Time frame: Baseline to 36 months
Change in Vascular Status
Systolic and diastolic blood pressure (mmHg).
Time frame: Baseline to 36 months
Change in Inflammatory Cytokines (blood samples)
CRP (mg/L), IL-6 (pg/mL), LBP (g/mL), BDNF (pg/mL)
Time frame: Baseline to 36 months
Change in Gastrointestinal Hormones (blood samples)
Postprandial GLP-1 (pg/mL) and fasting total ghrelin (pmol/L).
Time frame: Baseline to 36 months
Change in Adipokines (blood samples)
Fasting Leptin concentration (ng/mL)
Time frame: Baseline to 36 months
Change in Dietary Intake and Diet Quality Score (Web-based 24-hour dietary recall)
Healthy Eating Index (HEI) Score; Minimum: 0, Maximum: 100.
Time frame: Baseline to 36 months
Change in Eating Behaviors (Three-Factor Eating Questionnaire)
The Three-Factor Eating Questionnaire (TFEQ) will be used to assess three dimensions of eating behavior: cognitive restraint of eating, uncontrolled/disinhibited eating, and susceptibility to hunger. The questionnaire generates subscale scores for each dimension, with higher scores indicating greater levels of the respective eating behavior construct.
Time frame: Baseline to 36 months
Change in Eating Behaviors (Binge Eating Scale)
To assess the presence of certain binge eating behaviors that may be indicative of an eating disorder. The higher the score, the more binge eating behaviors is observed. The minimum score is 0 while the maximum score is 46. The final result allows to determine if the person has an absent (less than 17), moderate (between 18 and 26) or severe (more than 27) binging level.
Time frame: Baseline to 36 months
Change in Quality of Life (Laval Questionnaire)
Laval questionnaire evaluating quality of life on 6 aspects on a scale from 0 to 7, higher scores indicate better quality of life.
Time frame: Baseline to 36 months
Change in Depression and Anxiety Symptoms (Beck Depression Inventory)
Beck Depression Inventory. Evaluates severity of depressive symptoms using a validated questionnaire. Minimum score : 0; Maximum score : 63; Higher scores mean a worse outcome.
Time frame: Baseline to 36 months
Change in Anxiety
General Anxiety Disorder questionnaire (GAD-7). Total score ranges from 0 to 21, with an increasing score on the scale is indicating a worse anxiety state.
Time frame: Baseline to 36 months
Change in Quality of Sleep
Pittsburgh Sleep Quality Index questionnaire (PSQI) (19 self-assessment questions grouped into seven components). The scores for the seven components are summed to give an overall score that ranges from 0 to 21, with "0" indicating no difficulty and "21" indicating severe difficulty in all components. A score higher than 5 indicates problematic sleep in one or more components.
Time frame: Baseline to 36 months
Change in Physical Activity
Physical activity measured using accelerometry. Outcomes include daily moderate-to-vigorous physical activity (minutes/day) and sedentary time (minutes/day).
Time frame: Baseline to 36 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Dec 2030, 51 months later.
Of 137 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 51 months is above that.
Counting every sponsor, half of 138 studies reached it within 46 months; a quarter within 16 and three quarters within 132.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.